

CURRICULUM VITAE

PERSONAL INFORMATION

Name: Adrien Rousseau

Title: MD, PhD student, assistant professor in medical oncology

Contact:

Mail: adrien.rousseau@gustaveroussy.fr

Phone: +33142114211

Address: Gustave Roussy, France, 114 rue Edouard Vaillant 94800 Villejuif

Citizenship: French

Spoken languages: English (TOEIC 965/990 - C1 level), French (native)

PROFESSIONAL REGISTRATION

2025: Board certification in medical oncology (*France - Conseil National de l'Ordre des Médecins*)

RPPS Number: 10101877164

EDUCATION

2013-2019: Medical school - University of Tours (*Université de Tours*)

2019-2025: Medical oncology residency - Sorbonne University (*Sorbonne Université*)

2021: University diploma - Immuno-oncology - Paris Saclay University (*Université Paris-Saclay*)

2022-2023: Master of Science - Public health and clinical research - Paris Saclay University (*Université Paris-Saclay*)

2023: ESMO Examination certification

2024: MD Graduation, Doctor of Medicine - Sorbonne University (*Sorbonne Université*)

2024-present: Doctor of Philosophy (PhD) - Epidemiology - Paris Saclay University (*Université Paris-Saclay*)

CLINICAL POSITIONS HELD

2019-2025: Medical oncology resident - Gustave Roussy & Assistance Publique Hôpitaux de Paris (APHP), Paris, France. Rotations in medical oncology, haematology, intensive care, palliative care, radiation oncology

2025-present: Assistant professor in medical oncology - Gustave Roussy & Paris Saclay University, Villejuif, France. Department of Medical Oncology, thoracic oncology (Prof D. Planchard & B. Besse)

RESEARCH POSITIONS HELD

2022-2023: Research fellow - Gustave Roussy, Department of Biostatistics, INSERM UMR 1018 (Prof S. Michiels), Villejuif, France

2024-present: PhD student - Gustave Roussy, Department of Biostatistics, INSERM UMR 1018 (Prof S. Michiels), Villejuif, France

AREAS OF INTEREST / ACTIVITIES SUMMARY

Areas of interest: Thoracic oncology, Molecular oncology, Immunology, Clinical research, Transitional research, Causal inference, Biostatistics, Epidemiology

Assistant professor in the Medical Oncology Department and thoracic oncology team (Prof. Planchard & Besse) at Gustave Roussy Cancer Center & University of Paris-Saclay. I treat patients with lung

cancer, both in clinical trials and routine care. Sub-investigator in academic and industrial clinical trials. ICH-GCP (R3) last formation in October 2025.
I supervise medical students within the University of Paris-Saclay.
I am also a PhD student in public health, with a particular interest in pharmacoepidemiology and causal inference.

MEMBERSHIPS

French Society of Cancer (SFC)
Ethics & Cancer Committee of the Ligue Nationale contre le Cancer
European Society for Medical Oncology (ESMO)
American Society of Clinical Oncology (ASCO)
Société Française de Pharmacologie et Thérapeutique (SFPT)
Intergroupe Francophone de Cancérologie Thoracique (IFCT)

AWARDS & GRANTS

2024: Merit travel grant - ESMO congress Barcelona

SELECTED PUBLICATIONS

Number of publications in peer-reviewed journals: 29
As first/last author: 14
h-index: 8
ORCID ID: 0000-0001-8708-1664

Top 10 publications, ranked by highest impact factor:

- Rousseau A et al. Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab. JAMA Oncol. 2026
- Rousseau A et al. Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study. Lancet Reg Health Eur. 2024
- Rousseau A et al. Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung Cancer. JAMA Netw Open. 2025
- Delaye M, Rousseau A, et al. Obesity, cancer, and response to immune checkpoint inhibitors: Could the gut microbiota be the mechanistic link? Pharmacol Ther. 2023
- Rousseau A et al. Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Eur J Cancer. 2023
- Rousseau A et al. Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial. Eur J Cancer. 2025
- Ben-Ammar I, Rousseau A et al. Precision medicine for KRAS wild-type pancreatic adenocarcinomas. Eur J Cancer. 2024
- Rousseau A et al. Anti-TIGIT therapies for solid tumors: a systematic review. ESMO Open. 2023
- Rousseau A et al. Safety of solid oncology drugs in older patients: a narrative review. ESMO Open. 2024
- Matte P, Rousseau A et al. Perspectives of oncology residents on Master's Degree in Science (MSc) programs: a national descriptive study by the French Association of Residents in Oncology (AERIO). ESMO Open. 2024

Date: August 17th 2026

Academic Titles & Works

HOSPITAL ACTIVITIES SUMMARY

During my residency, I actively participated in the management of patients with solid cancers across numerous departments: outpatient clinics, inpatient wards, intensive care, palliative care, radiotherapy, and the hematology unit. I completed 117 night shifts (3 in 2019, 15 in 2020, 28 in 2021, 24 in 2022, 13 in 2023, 19 in 2024, 15 in 2025) and regularly took part in weekend on-call duties.

As a clinical fellow, I see about 30 patients per week in consultation, following patients with thoracic cancers, either enrolled in clinical trials or receiving standard care. I take part in the multidisciplinary tumor board. I am responsible for a half-day per week in the day hospital. I provide regular supervision for the residents caring for hospitalized patients with lung cancer (in a department totaling around 50 beds).

TEACHING & MENTORING

2025-present Medical Students

- Semiotics teaching
- Oncology teaching
- Biostatistics and public health teaching

2025-present Oncology residents

- Journal clubs
- Thoracic oncology teaching

MISSIONS IN SCIENTIFIC SOCIETIES

2019-2024 French society of medical oncology resident (*Association pour l'Enseignement et la Recherche des Internes d'Oncologie - AERIO*)

- Vice-president
- French representative of oncology resident
- Organization of several scientific congress for oncology residents

2020-2022 Paris Hospitals Interns' Union (*Syndicat des Internes des Hôpitaux de Paris - SIHP*)

- Parisian representative of oncology resident

2023-2025 French Society of Cancer (*Société Française du Cancer*)

- Member of scientific and administrative committee

2023-2025 Ethics & Cancer Committee of the Ligue Nationale contre le Cancer (*Comité éthique et cancer*)

INVITED ORAL PRESENTATIONS – NATIONAL (French-language conferences)

2022 International and French Oncology Days (IFODS)

2022 Immunity and Cancer Scientific Days (JSIC)

2023 Induction days for young oncologists (JRJO)

2026 International and French Oncology Days (IFODS)

INVITED POSTER PRESENTATIONS – INTERNATIONAL (English-language conferences)

2024 ESMO congress Barcelona
2025 ESMO congress Berlin
2025 ESMO Immunology congress London

PEER REVIEWED PUBLICATIONS (chronological order)

1. Rousseau A, Thieblemont C. Nouvelles AMMs au niveau européen : le brexucabtagene autoleucel dans les lymphomes du manteau réfractaires aux inhibiteurs de tyrosine kinase de Bruton (BTK) [New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor]. *Bull Cancer*. 2021 Feb;108(2):142-144. French. doi: 10.1016/j.bulcan.2020.12.006. Epub 2021 Jan 30. PMID: 33531153.
2. Rousseau A, Lafargue MC, Isnard-Bagnis C, Campedel L, Sahali D, Gougis P, Hénique C. Insuffisance rénale et symptômes rénaux associés aux thérapies moléculaires ciblées en oncologie [Renal failure and renal symptoms associated with molecular targeted therapies in oncology]. *Rev Prat*. 2021 Feb;71(2):198-205. French. PMID: 34160984.
3. Rousseau A, Ashton E, Naoun N, Cren PY, Gligorov J, Negrier S, Penel N, Spano JP. Guide sur le rôle du « Docteur Junior » en oncologie médicale [Manual for "Junior Doctors" in medical oncology]. *Bull Cancer*. 2021 Apr;108(4):377-384. French. doi: 10.1016/j.bulcan.2021.02.002. Epub 2021 Mar 19. PMID: 33745736.
4. Hilmi M, Ashton E, Delaye M, Giraud P, Neuzillet C, Spano JP, Gligorov J, Ollivier L, Rousseau A, Naoun N, Boilève A. Objectifs, motivations et difficultés des internes en phase socle en oncologie [Goals, motivations, and difficulties of young oncology residents]. *Bull Cancer*. 2022 Feb;109(2):119-129. French. doi: 10.1016/j.bulcan.2021.09.020. Epub 2021 Nov 19. PMID: 34809979.
5. Del Galy AS, Rousseau A, Capes A, Michonneau D, Robin M, de Fontbrune FS, Xhaard A, Frieri C, Adès L, Raffoux E, Himberlin C, Baudet M, Peffault de Latour R, Socié G. Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation. *Bone Marrow Transplant*. 2022 Sep;57(9):1365-1372. doi: 10.1038/s41409-022-01715-5. Epub 2022 Jun 2. PMID: 35654824.
6. Rousseau A, Laune Q, Ollivier L, Naoun N, Alexandre J, Giraud P, Azria D, Delaye M. État des lieux de la formation initiale de l'internat d'oncologie après la quatrième vague pandémie de la COVID-19 : une enquête AERIO-SFJRO [Formation of French oncology resident: A national survey]. *Bull Cancer*. 2022 Jul-Aug;109(7-8):834-843. French. doi: 10.1016/j.bulcan.2022.04.004. Epub 2022 Jun 4. PMID: 35672186; PMCID: PMC9167032.
7. Delaye M, Try M, Rousseau A, Lafargue MC, Saillant A, Binaud M, Andreani M, Rozenblat D, Campedel L, Corbaux P, Isnard-Bagnis C. Onco-nephrology: Physicians' Expectations About a New Subspecialty. *J Cancer Educ*. 2023 Jun;38(3):878-884. doi: 10.1007/s13187-022-02201-8. Epub 2022 Jul 15. PMID: 35840858.
8. Delaye M, Rousseau A, Try M, Massard C, Campedel L, Hilmi M, Bagnis C. Inclusion of patients with chronic kidney disease in randomized phase 3 clinical trials in patients with prostate, breast, lung, and colorectal cancer. *Cancer Med*. 2023 Feb;12(3):3172-3175. doi: 10.1002/cam4.5171. Epub 2022 Sep 26. PMID: 36156460; PMCID: PMC9939176.
9. Rousseau A, Zafrani L. Acute kidney injury after CAR-T cell infusion. *Bull Cancer*. 2024 Jul-Aug;111(7-8):748-753. doi: 10.1016/j.bulcan.2022.08.014. Epub 2022 Oct 8. PMID: 36220698.
10. Rousseau A, Tagliamento M, Auclin E, Aldea M, Frelaut M, Levy A, Benitez JC, Naltet C, Lavaud P, Botticella A, Grecea M, Chaput N, Barlesi F, Planchard D, Besse B. Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. *Eur J Cancer*. 2023 Mar;182:107-114. doi: 10.1016/j.ejca.2023.01.007. Epub 2023 Jan 13. PMID: 36758475.

11. Rousseau A, Parisi C, Barlesi F. Anti-TIGIT therapies for solid tumors: a systematic review. *ESMO Open*. 2023 Apr;8(2):101184. doi: 10.1016/j.esmoop.2023.101184. Epub 2023 Mar 16. PMID: 36933320; PMCID: PMC10030909.
12. Delaye M, Rousseau A, Mailly-Giacchetti L, Assoun S, Sokol H, Neuzillet C. Obesity, cancer, and response to immune checkpoint inhibitors: Could the gut microbiota be the mechanistic link? *Pharmacol Ther*. 2023 Jul;247:108442. doi: 10.1016/j.pharmthera.2023.108442. Epub 2023 May 18. PMID: 37210004.
13. Rousseau A, Auclin É. Cemiplimab en combinaison à la chimiothérapie dans le cancer bronchique non à petites cellules métastatiques [Cemiplimab in association to chemotherapy in advanced non-small cell lung cancer]. *Bull Cancer*. 2023 Oct;110(10):983-984. French. doi: 10.1016/j.bulcan.2023.05.008. Epub 2023 Jul 25. PMID: 37500386.
14. Laune Q, Varnier R, Rousseau A, Larnaudie A, Ghannam Y, Huguet F, Delaye M. Premiers docteurs juniors d'oncologie médicale : état des lieux et perspectives [Last year of residency for oncologists: Overview and perspectives]. *Bull Cancer*. 2024 Feb;111(2):142-152. French. doi: 10.1016/j.bulcan.2023.08.005. Epub 2023 Oct 14. PMID: 37845094.
15. Ben-Ammar I, Rousseau A, Nicolle R, Tarabay A, Boige V, Valéry M, Pudlarz T, Malka D, Gelli M, Fernandez-De-Sevilla E, Fuerea A, Tanguy ML, Rouleau E, Barbe R, Mathieu JRR, Jaulin F, Smolenschi C, Hollebecque A, Ducreux M, Boileve A. Precision medicine for KRAS wild-type pancreatic adenocarcinomas. *Eur J Cancer*. 2024 Jan;197:113497. doi: 10.1016/j.ejca.2023.113497. Epub 2023 Dec 15. PMID: 38134480.
16. A. Boilève, A. Rousseau, M. Hilmi, A. Tarabay, J.R.R. Mathieu, J. Cartry, S. Bedja, N. Goudarzi, C. Nicotra, M. Ngo-Camus, V. Boige, M. Valéry, T. Pudlarz, M.-A. Bani, P. Dartigues, L. Tselikas, A. Italiano, S. Coscone, M. Gelli, E. Fernandez-de-Sevilla, D. Malka, M. Annereau, F. Jaulin, C. Smolenschi, A. Hollebecque, M. Ducreux, Codon-specific KRAS mutations predict survival in advanced pancreatic cancer, *ESMO Gastrointestinal Oncology*, Volume 3, 2024, 100030, ISSN 2949-8198, <https://doi.org/10.1016/j.esmogo.2023.100030>.
17. Matte P, Rousseau A, Courtier B, Duval M, Laune Q, Duval J, Kfoury M, Delaye M. Perspectives of oncology residents on Master's Degree in Science (MSc) programs: a national descriptive study by the French Association of Residents in Oncology (AERIO). *ESMO Open*. 2024 May;9(5):103445. doi: 10.1016/j.esmoop.2024.103445. Epub 2024 Apr 25. PMID: 38669772; PMCID: PMC11061220.
18. Rousseau A, Michiels S, Simon-Tillaux N, Lolivier A, Bonastre J, Planchard D, Barlesi F, Remon J, Lavaud P, Aldea M, Frelaut M, Le Pechoux C, Botticella A, Levy A, Gazzah A, Foulon S, Besse B. Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study. *Lancet Reg Health Eur*. 2024 Jun 29;43:100970. doi: 10.1016/j.lanepe.2024.100970. PMID: 39040528; PMCID: PMC11262181.
19. Rousseau A, Géraud A, Geiss R, Farcet A, Spano JP, Hamy AS, Gougis P. Safety of solid oncology drugs in older patients: a narrative review. *ESMO Open*. 2024 Nov;9(11):103965. doi: 10.1016/j.esmoop.2024.103965. Epub 2024 Oct 30. PMID: 39481329; PMCID: PMC11567126.
20. Corbaux P, Binaud M, Rousseau A, Try M, Saillant A, Lafargue MC, Stocker N, Afchain P, Jamelot M, Isnard-Bagnis C, Campedel L, Delaye M. Patients' knowledge about renal secondary effects of anti-tumoral drugs and renal protection measures. *Support Care Cancer*. 2024 Nov 1;32(11):763. doi: 10.1007/s00520-024-08956-8. PMID: 39482406.
21. Rousseau A, Simon-Tillaux N, Michiels S, Derosa L, Laparra A, Planchard D, Remon J, Barlesi F, Lavaud P, Frelaut M, Parisi C, Gazzah A, Besse B, Foulon S. Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung Cancer. *JAMA Netw Open*. 2025 Sep 2;8(9):e2529225. doi: 10.1001/jamanetworkopen.2025.29225. PMID: 40928782; PMCID: PMC12423871.
22. Pudlarz T, Turpin A, Tissera NS, Hilmi M, Antoun L, Castet F, Lopez-Valbuena D, Rousseau A, Delaye M, Gelli M, Italiano A, Valéry M, Tarabay A, Boige V, Malka D, García-Galea E, Castillo G, Tian TV, Hollebecque A, Smolenschi C, Ducreux M, Macarulla T, Boilève A. Young-

onset biliary tract cancers: Characteristics, treatment patterns, and patient outcomes. *JHEP Rep.* 2025 Aug 11;7(11):101550. doi: 10.1016/j.jhepr.2025.101550. PMID: 41078701; PMCID: PMC12509751.

23. Rousseau A, Karimi M, Michiels S, Roubaud G, Maldonado X, Supiot S, McDermott R, Flechon A, Tombal B, Ronchin P, Berthold D, Berdah JF, Kacso G, Gravis G, Calabro F, Tartas S, Muracciole X, Ribault H, Fizazi K, Foulon S. Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial. *Eur J Cancer.* 2025 Nov 17;230:116024. doi: 10.1016/j.ejca.2025.116024. Epub 2025 Sep 27. PMID: 41045691.
24. Montégut L, Rousseau A, Ungolo C, Derosa L, Fidelle M, Alves Costa Silva C, Routy B, Zitvogel L, Besse B, Pasolli E, Kroemer G. Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer. *Oncoimmunology.* 2025 Dec;14(1):2528955. doi: 10.1080/2162402X.2025.2528955. Epub 2025 Jul 4. PMID: 40613596; PMCID: PMC12233713.
25. Matte P, Saillant A, Corbaux P, Dominjon E, Rousseau A, Jaffrelot L, Isnard-Bagnis C, Binaud M, Delaye M. Hydration practices during cisplatin administration: a national multicenter survey. *Support Care Cancer.* 2025 Nov 25;33(12):1127. doi: 10.1007/s00520-025-10189-2. PMID: 41288783.
26. N. Taranto, M. Duval, C. Raynaud, A. Boilève, N. Naoun, A. Rousseau, E. Ashton, L. Ollivier, J. Alexandre, F. Huguet, M. Kfoury, M. Delaye, M. Hilmi. Declining research interest among oncology residents: insights into the academic career from a nationwide longitudinal study in France, *ESMO Open*, Volume 11, Issue 1, 2026, 106025, ISSN 2059-7029, <https://doi.org/10.1016/j.esmoop.2025.106025>.
27. Claudia Parisi, Andrea De Giglio, Marco Banini, Marco Tagliamento, Adrien Rousseau, Maxime Frelaut, Francesca Fusco, Francesco Mantuano, Valentina Favorito, Federico Cappuzzo, Andrea Ardizzoni, Jordi Remon, Benjamin Besse, David Planchard, Fabrice Barlesi, Non-Small Cell Lung Cancer (NSCLC) in Vulnerable and Special Populations: Towards Personalized Care, *Journal of Thoracic Oncology*, 2026, 103705, ISSN 1556-0864, <https://doi.org/10.1016/j.jtho.2026.103705>.
28. Rousseau A, Foulon S, Planchard D, Remon J, Barlesi F, Lavaud P, Frelaut M, Aldea M, Parisi C, Gazzah A, Le Pechoux C, Botticella A, Levy A, Simon-Tillaux N, Michiels S, Besse B. Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab. *JAMA Oncol.* 2026 Apr 9. doi: 10.1001/jamaoncol.2026.0669. Epub ahead of print. PMID: 41954917.
29. Adrien Rousseau, Astrid Foix-Colonier, Joël Luu, Stéphanie Foulon, Benjamin Besse, V. Valentine Laizet, Khalil-Jonathan Jewiti-Rigondza, Alaeddine Sidhom, Nahla Nacef, Aline Gauthier, M. Monia Ezzalfani, Julia Bonastre. Impact of immunotherapy on overall survival and healthcare costs in advanced/metastatic lung cancer: A real-world study in France, *Lung Cancer*, 2026, 109549, ISSN 0169-5002, <https://doi.org/10.1016/j.lungcan.2026.109549>.